While breast cancer is not a focus of the current clinical trials for RET-selective inhibitors, a wealth of preclinical data summarized here suggest that RET may have a critical role in the future of breast cancer therapy at varied stages of disease, in multiple drug combinations, and a variety of tumor subtypes. This evidence concerns the gene RET and breast carcinoma.